In the last few years, a number of reports have clearly shown that pulmonary T lymphocytes
have evolved a number of effector mechanisms to respond to foreign antigens, ranging from …

BACKGROUND: Most issues concerning pharmacotherapy of pulmonary sarcoidosis have
not been resolved in clinical trials. The objective was to survey sarcoidosis experts …

The focus of this review is current knowledge about the epidemiology, clinical
manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary …

Granulomatous inflammation in the lung may occur from a variety of causes. Many of these
are the result of specific antigens that reach the lung and induce a granulomatous response …

Introduction: Sarcoidosis is a systemic disease of unknown etiology characterized by the
development of non-caseating epitheloid granulomas. The lungs are the most commonly …

Background Although several serum markers have shown their ability to reflect lymphocytic
alveolitis and disease progression in pulmonary sarcoidosis, to our knowledge no prior …

A disease of apparently altered immunity, sarcoidosis is manifested in multiple organ
systems of the body, but especially in the lungs, eyes, skin, and reticuloendothelial system …

For treatment of sarcoidosis, one should develop a long-term management plan. Factors to
be considered include the organ involvement and severity of symptoms. Different organ …

Sarcoidosis is a systemic granulomatous disease that frequently involves the lung. Although
classically thought of as a restrictive lung disease, airway obstruction has become a …

Evidence-based treatment guidelines do not exist for most sarcoidosis clinical
manifestations. Therefore, clinical care of these patients must rely on expert opinion …